Endophthalmitis management study. Report #1. Protocol.


Journal

Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376

Informations de publication

Date de publication:
07 2021
Historique:
entrez: 19 6 2021
pubmed: 20 6 2021
medline: 1 7 2021
Statut: ppublish

Résumé

To date, the Endophthalmitis Vitrectomy Study (EVS) has remained the hallmark of evidence-based management of acute bacterial endophthalmitis after cataract surgery with an intraocular lens. In the last quarter-century since its publication, several studies have reported that the microbiological spectrum of endophthalmitis is not the same across the world; there is emerging antibiotic resistance of gram-negative microorganisms to the EVS recommended antibiotics; there are newer molecules that could cross the blood-retinal barrier; the advances in vitreous surgery have become safer than before, and there are newer methods of microbiological evaluation. One of the often-mentioned drawbacks of the EVS was not recruiting grossly infected eyes with poor visibility of the iris and vitreous. Keeping these factors in mind, a new prospective multi-centered randomized study, the Endophthalmitis Management Study (EMS), is designed. The EMS will recruit all post-cataract surgery endophthalmitis patients irrespective of severity (including suspected fungal infection); the EMS will use quantifiable inflammatory score instead of the presenting vision to allocate for surgery, randomize the eyes to two different combinations of intravitreal antibiotics and use the newer microbiological diagnostic techniques. We believe the EMS findings will complement the EVS recommendations.

Identifiants

pubmed: 34146061
pii: IndianJOphthalmol_2021_69_7_1936_318581
doi: 10.4103/ijo.IJO_199_21
pmc: PMC8374761
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1936-1941

Déclaration de conflit d'intérêts

None

Références

Mediators Inflamm. 2012;2012:196094
pubmed: 22973073
Clin Ophthalmol. 2019 Feb 05;13:243-251
pubmed: 30787589
Br J Ophthalmol. 2008 Feb;92(2):241-4
pubmed: 17993577
J Ophthalmic Inflamm Infect. 2014 Sep 10;4:22
pubmed: 25667683
Eye (Lond). 2019 Jul;33(7):1090-1095
pubmed: 30792523
Ophthalmology. 2000 Mar;107(3):486-9
pubmed: 10711885
Arch Ophthalmol. 1995 Dec;113(12):1479-96
pubmed: 7487614
Indian J Ophthalmol. 2017 Dec;65(12):1403-1406
pubmed: 29208821
Arch Ophthalmol. 2008 Apr;126(4):559-61
pubmed: 18413530
Int J Syst Evol Microbiol. 2000 Jul;50 Pt 4:1553-1561
pubmed: 10939663
J Ophthalmic Inflamm Infect. 2016 Dec;6(1):45
pubmed: 27882513
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1200-5
pubmed: 16235062
Am J Ophthalmol. 2006 May;141(5):938-40
pubmed: 16678510
Arch Ophthalmol. 2006 Feb;124(2):178-82
pubmed: 16476886
Sci Rep. 2019 Jan 29;9(1):844
pubmed: 30696908
Acta Ophthalmol. 2009 Sep;87(6):648-52
pubmed: 19508273
Br J Ophthalmol. 1999 Sep;83(9):1050-5
pubmed: 10460774
J Ophthalmol. 2017;2017:6285869
pubmed: 28589037
Retina. 2006 May-Jun;26(5):545-8
pubmed: 16770261
Br J Ophthalmol. 2011 Oct;95(10):1385-8
pubmed: 21289020
Ophthalmology. 1992 Apr;99(4):483-6
pubmed: 1584563
Clin Exp Ophthalmol. 2017 Apr;45(3):254-260
pubmed: 27616274

Auteurs

Taraprasad Das (T)

Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, Kallam Anji Reddy Campus, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Vivek P Dave (VP)

Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, Kallam Anji Reddy Campus, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Avantika Dogra (A)

Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, Kallam Anji Reddy Campus, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Joveeta Joseph (J)

Jhaveri Microbiology Center, Kallam Anji Reddy Campus, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Savitri Sharma (S)

Jhaveri Microbiology Center, Kallam Anji Reddy Campus, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH